
Qiagen N.V.
QGENNYSEHealthcareMedical - Diagnostics & Research
Previous close
$44.07
−$0.83 · -1.85%
QGEN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
94
Deep Value
Momentum
56
Neutral
Sentiment
63
Bullish
Risk resilience
59
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteQiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- NL
- CEO
- Thierry Bernard
- Listed since
- Jun 28, 1996
- Employees
- 5,500
Market position
Day range
Current $44.07
52-week range
Current $44.07
- Open
- $44.29
- Previous close
- $44.90
- Volume
- 2.9M
- 1.08× average
- Average volume
- 2.68M
- Average daily volume
- Market cap
- 9.09B USD
- Beta
- 0.62
- Market reference 1
- 50-day average
- $40.6864
- +8.32% above average
- 200-day average
- $42.7616
- +3.06% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 10.66B USD
- P/E (TTM)
- 22.6×
- P/B (TTM)
- 2.71×
- P/S (TTM)
- 4.33×
- EV / EBITDA
- 14.86×
- Earnings yield
- 4.32%
- Free cash flow yield
- 4.60%
- Dividend yield
- 5.99%
Profitability & efficiency
- Gross margin
- 61.82%
- Operating margin
- 25.33%
- Net margin
- 19.49%
- Return on equity
- 11.25%
- Return on assets
- 6.75%
- Return on invested capital
- 7.80%
Financial health
- Debt / equity
- 0.49×
- Current ratio
- 3.9×
Earnings
- EPS beat rate
- 73%
- 8 beats, 1 miss, 2 met estimates
- Average EPS surprise
- +3.50%
- 11 comparable reports
- Latest EPS result
- 0.62
- Estimate 0.6 · Beat by 3.68%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
30 ratingsQGEN news
QGEN peers
ETFs holding QGEN
Funds reporting this stock among their holdings, ordered by reported position size.
First Trust Health Care AlphaDEX FundFXH21.33M1.84%1.17B USD0.61%$135.22+1.01%
Invesco Biotechnology & Genome ETFPBE11.58M2.91%401.81M USD0.58%$97.59+1.07%
Vanguard Russell 1000 Value ETFVONV5.32M0.02%23.1B USD0.06%$112.82+0.43%
VanEck Biotech ETFBBH4.91M1.05%476.57M USD0.35%$241.23+1.74%
State Street SPDR US Large Cap Low Volatility Index ETFLGLV3.45M0.28%1.22B USD0.12%$188.55+0.23%
Global X - Genomics & Biotechnology ETFGNOM3.01M3.18%94.83M USD0.50%$66.77+2.88%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.62M0.10%2.71B USD0.20%$69.24+0.92%
Vanguard Russell 1000 ETFVONE1.4M0.01%11.5B USD0.06%$347.1+0.40%
First Trust Health Care AlphaDEX FundFXH- Market value
- 21.33M
- Weight
- 1.84%
- AUM
- 1.17B USD
- Expense ratio
- 0.61%
- Price / 1D
- $135.22+1.01%
Invesco Biotechnology & Genome ETFPBE- Market value
- 11.58M
- Weight
- 2.91%
- AUM
- 401.81M USD
- Expense ratio
- 0.58%
- Price / 1D
- $97.59+1.07%
Vanguard Russell 1000 Value ETFVONV- Market value
- 5.32M
- Weight
- 0.02%
- AUM
- 23.1B USD
- Expense ratio
- 0.06%
- Price / 1D
- $112.82+0.43%
VanEck Biotech ETFBBH- Market value
- 4.91M
- Weight
- 1.05%
- AUM
- 476.57M USD
- Expense ratio
- 0.35%
- Price / 1D
- $241.23+1.74%
State Street SPDR US Large Cap Low Volatility Index ETFLGLV- Market value
- 3.45M
- Weight
- 0.28%
- AUM
- 1.22B USD
- Expense ratio
- 0.12%
- Price / 1D
- $188.55+0.23%
Global X - Genomics & Biotechnology ETFGNOM- Market value
- 3.01M
- Weight
- 3.18%
- AUM
- 94.83M USD
- Expense ratio
- 0.50%
- Price / 1D
- $66.77+2.88%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP- Market value
- 2.62M
- Weight
- 0.10%
- AUM
- 2.71B USD
- Expense ratio
- 0.20%
- Price / 1D
- $69.24+0.92%
Vanguard Russell 1000 ETFVONE- Market value
- 1.4M
- Weight
- 0.01%
- AUM
- 11.5B USD
- Expense ratio
- 0.06%
- Price / 1D
- $347.1+0.40%
Continue in GoAI
Research QGENresearch.disclaimer











